Experts seek to homogenise the approach of thyroid cancer Spain.
The Thyroid Cancer Group of the English Society of Endocrinology and Nutrition (SEEN) is organizing, under the auspices of Genzyme, a symposium on the disease.
- The protocol continues today in our country is the best, but it was found that clinical practice is not uniform - This disease has a low but increasing incidence in the northwest English, according to an epidemiological study of 2009 conducted by the Hospital Universitario de Vigo - In areas of Galicia, where extremely low iodine intake predominantly follicular thyroid cancers, which are often particularly aggressive-Ionising radiation is the most recognized trigger of the disease and is also shown that populations near areas present volcanic prevalence ten times higher than other areas "Another of the issues addressed at the symposium has been monitoring biochemical differentiated thyroid carcinoma.
Santiago de Compostela, May 18, 2011. Differentiated thyroid cancer is the most frequent endocrine cancer, however, is rare compared with other types of cancers.
In general, the average age of diagnosis is between 40 and 53 years , being especially prevalent among white women. In order to update knowledge about its approach, the Thyroid Cancer Group of the English Society of Endocrinology and Nutrition (SEEN) has organized in the context of 53 SEEN Congress and sponsored by Genzyme, the symposium "taking a position in relation to current treatment protocols Node and differentiated thyroid cancer; Creating Multidisciplinary Committees" . has low but increasing incidence, Spain occupies an intermediate position compared with other European countries . The trend is the same in the case of northwestern English, according to an epidemiological study of 2009 conducted by the Hospital Universitario de Vigo. Of the 322 new cases registered between 1978 and 2001 in the hospital (for a stock 500,000 inhabitants), 76% were papillary thyroid cancers, with special emphasis among women . On the other hand, "in areas of Galicia where extremely low iodine intake predominantly follicular thyroid cancers, which tend to be more aggressive," said Dr. Ricardo V. García-Mayor, Chief of Endocrinology and Nutrition from General Hospital of Vigo (Pontevedra ). "Although ionizing radiation are the most recognized trigger of the disease, is also shown that populations near volcanic areas have a prevalence ten times higher than other areas, " points. Among the latest developments in the approach of differentiated thyroid cancer, the expert referred to is giving promising results using genetic techniques in the diagnosis of the disease. Also referred to the "breakthrough that has led to the staging of tumors of the face to the personalization of surgical treatment, and the establishment of different protocols depending on the forecast track," he explains. The protocol followed in Spain, the best possible.
According to Dr. José Manuel Gómez Sáez, coordinator of the Thyroid Cancer the SEEN, pointed as a major objective of the meeting "coordination of multidisciplinary approach of the nodule and differentiated thyroid cancer in Spain following the model of the European consensus attitude of thyroid cancer and American guidance, revised in November 2009 ". Given the nature of this cancer, "made necessary efforts and expertise of specialists, including an endocrinologist should be the main coordinator for who first see these patients," he explains. "The protocol that is followed today in our country is the best, but we found that the practice is not uniform ". Another of the topics discussed at the symposium was the biochemical monitoring differentiated thyroid carcinoma, which " is based on the determination of basal or stimulated thyroglobulin to recombinant human TSH, along with ultrasound and other techniques possible vertical " says Dr. Gómez Sáez. The limitation of this process is in its complexity, mainly due to the molecular structure and some analytical interferences has to be taken into account, "he says. Finally, we have pooled the new criteria of surgical treatment of this cancer and the proposals of Nuclear Medicine in the diagnosis and treatment. About Genzyme
Genzyme, one of the leading biotech companies worldwide, is focused on achieving the greatest positive impact on the lives of people affected by serious illness. Since its founding in 1981, Genzyme has developed innovative treatments in several therapeutic areas, providing new hope to patients. Today, Genzyme approximately 10,000 employees are dedicated to serving patients in nearly 100 countries. Genzyme's products are focused on rare inherited diseases, kidney disease, orthopedics, cancer, transplant and immune diseases. Our commitment to innovation continues today, with major programs focused on developing therapeutic areas mentioned, as well as cardiovascular, neurodegenerative diseases and other areas with unmet medical needs. Genzyme part of Sanofi-aventis group.
Sanofi-aventis, a leading pharmaceutical company worldwide, discovers, develops and distributes therapeutic solutions to improve the lives people . -----------------
SANOFI "IMPROVE PEOPLE'S LIVES?
he has done with women, both Europe and Latin America with its Agreal / AGRADIL / ACLIMAFEL / veralipride?
HUNDREDS AND HUNDREDS OF WOMEN WITH THYROID serious problems, REMOVAL OF LYMPH AND RETURNED TO REPRODUCIRSELES.
OTHER OF "MANY malice" HID WITH veralipride / veralipride.
HAVE "TRAFFIC AND TRAFFIC WITH THE" HEALTH OF MILLIONS OF WOMEN.
SANOFI:
"NO MORE malice" WITH "Agreal / veralipride IN SPAIN ".
http://www.acceso.com/es_ES/notas-de-prensa/expertos-buscan-homogeneizar-el-abordaje-del-cancer-de-tiroides-en-espana/75407/
0 comments:
Post a Comment